180 Life Sciences Corp

180 Life Sciences Corp(ATNF)の株式分析

$7.040

-0.527 (-7.49%)終値時点

Loading chart…
High
7.240
Open
6.840
VWAP
6.86
Vol
11.63M
Mkt Cap
1.43M
Low
6.290
Amount
79.77M
EV/EBITDA, TTM
0.00

180 Life Sciences Corp. is a biotechnology company, which focuses on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. Its programs include Anti-TNF (Clinical), Synthetic Cannabinoid Analogs (SCAs), and a7nAChR (Preclinical). The Company also operates a back-end technology platform to operate an online blockchain casino.

バリュエーション指標

The current forward P/E ratio for 180 Life Sciences Corp (ATNF) is -0.01, compared to its 5-year average forward P/E of -9.42.

Forward P/E

Fair
5Y Average P/E
-9.42
Current P/E
-0.01
割高
25.00
割安
-43.85

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
割高
0.00
割安
0.00

Forward P/S

Fair
5Y Average P/S
4.28
Current P/S
0.19
割高
16.51
割安
-7.96

ATNF FAQ — answered by Alphio AI

180 Life Sciences Corp. is a biotechnology company, which focuses on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. Its programs include Anti-TNF (Clinical), Synthetic Cannabinoid Analogs (SCAs), and a7nAChR (Preclinical). The Company also operates a back-end technology platform to operate an online blockchain casino. It operates in the Technology sector (PHARMACEUTICAL PREPARATIONS industry).

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める